Is the market overreacting to the coronavirus? Why do so many clinical trials go unfilled? And how do you pronounce “Martin Shkreli”?
We discuss all that and more on this, the 100th episode of “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the stock market’s frenetic reaction to the novel coronavirus outbreak and how it’s affecting biotech companies. Then, we talk to Todd Mercer, a patient from Michigan with a rare type of cancer, about how difficult it can be to enroll in a clinical trial. Later, we revisit the first episode of this podcast to update the big stories of yesteryear and discover just how embarrassed we should be. Finally, we field questions from listeners, covering genetically engineered pets, putting a dollar value on human life, and the importance of gossip.
For more on what we cover, here’s the latest on the coronavirus, and here’s our first episode.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
Thank you so much for highlighting Todd Mercer and the quest for clinical trials. His points are so important and as a fellow patient (who was also at the COLONTOWN event), I strongly believe we need this genetic Match.com to happen. We appreciate that STAT, as a premiere health journalist organization, is spreading the word.
Thank you so much for highlighting Todd Mercer and the quest for clinical trials. His points are so important and as a fellow patient (who was also at the COLONTOWN event), I strongly believe we need this genetic Match.com to happen. As one of the premiere health journalist organizations we appreciate you spreading the word.
Thank you for highlighting the frustrations of cancer patients and trial admissions. The process if finding an appropriate trial for a layperson is daunting. Seems there should be a universal registry that could alert both patients and trial coordinators. I see advertisements daily for “love connection” apps and websites and wonder why we don’t have something similar for tumors that could easily match genetic makeup and trials.
Screw you. They are paying for the research. Let Bernie and Fidel take care of you. Die commie.
Comments are closed.